AbbVie Acquires Aliada, Strengthens Alzheimer's Pipeline
AbbVie acquires Aliada Therapeutics to advance ALIA-1758, an Alzheimer's drug in Phase 1.
Breaking News
Dec 12, 2024
Simantini Singh Deo

AbbVie has officially finalised its acquisition of Aliada Therapeutics, merging the company into its operations. Aliada's key experimental drug, ALIA-1758, is a leading anti-pyroglutamate amyloid beta (3pE-Aβ) antibody designed to treat Alzheimer's disease. This treatment is currently undergoing a Phase 1 clinical trial. ALIA-1758 uses its innovative blood-brain barrier (BBB) — crossing technology, significantly improving targeted therapies' delivery to the central nervous system (CNS).
Dawn Carlson, M.D., M.P.H., vice president of neuroscience development at AbbVie, said in a statement, "Alzheimer's disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age. With the acquisition complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform."